TITLE

Benzonatate for opioid-resistant cough in advanced cancer

AUTHOR(S)
Doona, M.; Walsh, D.
PUB. DATE
January 1998
SOURCE
Palliative Medicine;1998, Vol. 12 Issue 1, p55
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chronic cough is a distressing symptom experienced by approximately 37% of patients with advanced cancer. Palliation of chronic nonproductive cough should always first address the underlying cause but in some patients chronic, nonproductive cough persists and antitussive agents are required. Opioids are the gold standard cough suppressants, of which codeine is the most widely used; patients with an opioid-resistant cough often prove to be a therapeutic challenge. We report three patients with an opioid-resistant cough who achieved symptomatic relief with the peripherally acting nonopioid drug benzonatate.
ACCESSION #
4088231

 

Related Articles

  • New heartburn drug hype.  // HealthFacts;Jun95, Vol. 20 Issue 193, p2 

    Reports on the Food and Drug Administration's approval of the over-the-counter antiulcer drugs Tagamet and Pepcid. Estimated sales garnered by the two drugs in 1994.

  • Help for patients who have difficulty swallowing ulcer Rx capsules.  // Modern Medicine;Apr96, Vol. 64 Issue 4, p21 

    Reports on the easier intake of lansoprazole delayed-release capsules, indicated for the short-term treatment of ulcers, erosive esophagitis and pathological hypersecretory conditions, for patients who have a hard time swallowing the capsules.

  • Sulfasalazine.  // Reactions Weekly;5/15/2010, Issue 1301, p46 

    The article describes the case of a 19-year-old woman with ulcerative colitis who experienced drug rash, eosinophilia and systemic symptoms (DRESS) syndrome while under sulfasalazine therapy.

  • Proton pump inhibitors: New drugs and indications. Mears, James M.; Kaplan, Barbara // American Family Physician;1/1/1996, Vol. 53 Issue 1, p285 

    Presents recently developed proton pump inhibitors and new indications. Pharmacology; Pharmacokinetics; Dosage and cost; Adverse drug reactions; Lansoprazole (Prevacid) and pantoprazole (NC-1300); Drug-to-drug interactions; FDA-approved indications; Unapproved therapeutic uses.

  • Omeprazole, H2 blockers, and polyarthralgia: Case-control study. Meier, Christoph R.; Jick, Hershel // BMJ: British Medical Journal (International Edition);11/15/97, Vol. 315 Issue 7118, p1283 

    Compares the relative risk of developing acute idiopathic polyarthralgia, during and after exposure to omeprazole, ranitidine or cimetidine, antiulcer drugs used for similar indications. Nested case-control analysis using data from a British general practitioner research database; Subjects...

  • Ranitidine and duodenal ulceration. Roberts, D. M. // Journal of the Royal Society of Medicine;Sep1982, Vol. 75 Issue 9, p754 

    A letter to the editor is presented in response to the article on ranitidine and duodenal ulceration, in the May 1982 issue.

  • Cimetidine and the Cytochrome P-450 System. Leiber, Bernard L.; Antell, Laura A. // American Journal of Gastroenterology;Sep1988, Vol. 83 Issue 9, p1006 

    Presents a letter to the editor in response to the article "Hepatic Effects of drugs Used in the Treatment of Peptic Ulcer Disease," by J. H. Lewis, in the 1987 issue.

  • cimetidine.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p454 

    A definition of the term "cimetidine," which refers to a hydrogen-receptor antagonist inhibiting the secretion of stomach acid is presented.

  • Zantac.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2513 

    A definition of the term "Zantac" which refers to ranitidine is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics